Covance Pharma: Innovative drugs have the characteristics of high technology, high risk, and high added value, with many uncertainties.

Kexing Pharmaceutical issues announcement on abnormal stock trading fluctuations. The company's multiple innovative drug projects are still in the pre-clinical stage. The company specifically reminds investors that innovative drugs have the characteristics of high technology, high risk, and high added value, and the drug development process from research, clinical trials, approval to production is long and complex. There are still many uncertainties in the subsequent research progress, research results, approval results, market sales, etc.